214 related articles for article (PubMed ID: 11794228)
1. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Campbell P
N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
[No Abstract] [Full Text] [Related]
2. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Araujo R; Agustí A
Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
[No Abstract] [Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Chesebro JH; Badimon JJ
N Engl J Med; 1998 May; 338(21):1539-41. PubMed ID: 9593795
[No Abstract] [Full Text] [Related]
5. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
[TBL] [Abstract][Full Text] [Related]
6. Tirofiban in unstable coronary disease.
Liron M
N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651
[No Abstract] [Full Text] [Related]
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
8. Fast, aggressive treatment for myocardial infarction urged.
Mitka M
JAMA; 2000 Dec; 284(23):2985-6. PubMed ID: 11122567
[No Abstract] [Full Text] [Related]
9. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
10. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
[No Abstract] [Full Text] [Related]
12. Routine vs selective invasive strategies in acute coronary syndromes.
Bavry AA; Kumbhani DJ
JAMA; 2005 Dec; 294(22):2844-5; author reply 2845-6. PubMed ID: 16352787
[No Abstract] [Full Text] [Related]
13. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
14. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Perez de Arenaza D; Bakhai A; Flather M
N Engl J Med; 2001 Nov; 345(21):1573; author reply 1574-5. PubMed ID: 11794229
[No Abstract] [Full Text] [Related]
15. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
Brener SJ
J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
[No Abstract] [Full Text] [Related]
16. GUSTO IV: expanding therapeutic options in acute coronary syndromes.
Lincoff AM
Am Heart J; 2000 Dec; 140(6 Suppl):S103-14. PubMed ID: 11100004
[No Abstract] [Full Text] [Related]
17. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
18. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Mehta SR;
J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet therapy for ischemic heart disease.
Lange RA; Hillis LD
N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308
[No Abstract] [Full Text] [Related]
20. Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied.
Goldberg L; Mekel J
Am J Cardiol; 2000 Dec; 86(12):1401-2. PubMed ID: 11192745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
